Compare New York Times Co (NYT) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs TransMedics Group Inc — how do they compare? New York Times Co trades at $66.6 (market cap $10.74B), while TransMedics Group Inc trades at $78.32 (market cap $2.74B). The key difference: New York Times Co is far larger — about 3.9× TransMedics Group Inc's market cap, and New York Times Co pays a 1.38% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold New York Times Co for 81 Days and TransMedics Group Inc for 24 Days on average.
| NYT | TMDX | |
|---|---|---|
Market Cap | $10.74B | $2.74B |
Volume | 2,096,352 | 949,331 |
Sector | Media | Health |
52-Week High | $85.86 | $150.42 |
52-Week Low | $54.66 | $61.99 |
Typical Hold Time | 81 Days | 24 Days |
Enterprise Value | $10.14B | $3.13B |
Dividend Yield | 1.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The New York Times Company (NYSE: NYT) trades at $65.64, up 1.14% today, with a bullish technical signal and strong fundamentals. Revenue grew from $2.3B in 2022 to $2.8B in 2025, with net income margin expanding to 12.17%. Recent earnings beats and a declared $0.23 dividend highlight operational strength, though a shareholder lawsuit presents headline risk.
Outlook is positive given consistent earnings outperformance and analyst consensus target of $84.00, implying 28% upside. Key risks include the pending lawsuit's impact on reputation and competitive pressures in digital media. Cash flow generation remains robust, supporting dividend sustainability and growth initiatives.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
